江苏硕世生物科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性 和完整性依法承担法律责任。 证券代码：688399 证券简称：硕世生物 公告编号：2023-022 江苏硕世生物科技股份有限公司（以下简称"公司"）近日 收到国家药品监督管理局(以下简称"国家药监局")签发的医 疗器械注册证（体外诊断试剂）,具体信息如下: 二、对公司的影响 上述《医疗器械注册证》的取得，丰富了公司产品种类，扩 充了公司在体外诊断领域的布局，不断满足多元化的临床需求， 将增强公司综合竞争力，有利于进一步提高公司的市场拓展能 力。 三、风险提示 1 江苏硕世生物科技股份有限公司董事会 2023 年 8 月 12 日 2 一、医疗器械注册证的具体情况 序号 产品名称 注册编号 注册证 有效期 注册 分类 预期用途 1 EB 病毒核酸检测试 剂盒（荧光 PCR 法） 国械注准 20233401154 至 2028 年 8 月 9 日 三类 本试剂盒适用于体外定量 检测外周血样本中 EB 病毒 DNA 上述产品获证后的实际销售 ...

证券代码：688399 证券简称：硕世生物 公告编号：2023-015 江苏硕世生物科技股份有限公司 关于参加 2022 年度体外诊断专场 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 06 月 12 日(星期一)下午 14:00-15:00 会议召开方式：视频和线上文字互动 视频和线上文字互动平台：上海证券交易所上证路演中心（网 址：https://roadshow.sseinfo.com/） 投资者可于 2023 年 6 月 9 日(星期五)17:00 前通过邮件方式将 需要了解和关注的问题发送至公司邮箱 sssw@s-sbio.com，公司将在 文字互动环节对投资者普遍关注的问题进行回答。 江苏硕世生物科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发布公司 2022 年年度报告，为加强与投资者的深入交 流，使投资者更加全面、深入地了解公司情况，公司参与了由上海证 券交易所主办的 2022 年度体外诊断专场集体业绩说明会，欢迎 ...

证券代码：688399 证券简称：硕世生物 公告编号： 2023-013 江苏硕世生物科技股份有限公司 关于召开 2022 年度暨 2023 年第一季度业绩说明会 的公告 （二） 会议召开地点：上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 会议召开方式：上证路演中心视频直播和网络互动 投资者可于 2023 年 05 月 09 日(星期二) 至 05 月 15 日(星期 一)16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通 过公司邮箱 sssw@s-sbio.com 进行提问。公司将在说明会上对投资者 普遍关注的问题进行回答。 江苏硕世生物科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 27 日发布公司 2022 年年度报告及 2023 年第一季度报告，为 便于广大投资者更全面深入地了解公司 2022 年度及 2023 年第一季 度经营成果、财务状况，公司计划于 2023 年 0 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥94,053,695.57, representing a decrease of 93.82% compared to the same period last year[2] - The net profit attributable to shareholders was -¥19,424,028.96, a decline of 103.08% year-over-year[2] - Basic and diluted earnings per share were both -¥0.33, reflecting a decrease of 103.06%[2] - Total revenue for Q1 2023 was CNY 94,053,695.57, a significant decrease of 93.83% compared to CNY 1,521,902,378.62 in Q1 2022[15] - Net profit for Q1 2023 was a loss of CNY 19,424,028.96, compared to a profit of CNY 631,070,096.78 in Q1 2022, indicating a decline of 103.08%[16] Cash Flow - The net cash flow from operating activities was -¥226,392,877.94, down 146.17% from the previous year[2] - In Q1 2023, the net cash flow from operating activities was -226,392,877.94, a significant decline compared to 490,379,975.90 in Q1 2022[19] - The total cash outflow from operating activities was 497,068,809.17, compared to 866,900,896.52 in the same quarter last year[19] - Cash inflow from sales and services received was 214,177,789.24, a decrease from 1,334,170,582.58 in Q1 2022[18] - The total cash and cash equivalents at the end of Q1 2023 were 979,636,103.79, down from 1,062,017,901.88 at the end of Q1 2022[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,715,437,080.57, a decrease of 3.59% from the end of the previous year[3] - Total liabilities as of Q1 2023 amounted to CNY 956,710,813.88, down from CNY 1,112,849,694.21 in the previous year, a reduction of 14.06%[15] - The equity attributable to shareholders was ¥3,758,726,266.69, down 0.51% compared to the previous year[3] - The company's total assets as of March 31, 2023, were ¥4,715,437,080.57, down from ¥4,890,999,989.86, representing a decrease of approximately 3.6%[13] Research and Development - Research and development expenses totaled ¥34,288,082.49, which is an increase of 26.29% year-over-year, accounting for 36.46% of operating revenue, up 34.68 percentage points[2] - Research and development expenses for Q1 2023 were CNY 34,288,082.49, an increase of 26.00% compared to CNY 27,149,529.76 in Q1 2022[16] Investment Activities - Total cash inflow from investment activities reached 2,114,275,580.39, up from 517,215,844.18 in the same period last year[19] - The cash outflow from investment activities was 2,324,226,649.49, compared to 619,363,626.32 in Q1 2022, resulting in a net cash flow from investment activities of -209,951,069.10[19] Shareholder Information - The company has a total of 15,600,000 shares held by its largest shareholder, accounting for 26.61% of the total shares[10] Other Information - The significant decline in revenue was primarily due to a sharp decrease in income from COVID-related products and services[6] - The company has not disclosed any significant new strategies or product developments during the reporting period[11] - The company has not disclosed any new product developments or market expansion strategies in the provided financial report[17]

Financial Performance - The company reported a net profit of 0 million RMB for the year 2022, with no cash dividends or stock bonuses proposed for distribution [7]. - The company has not yet achieved profitability since its listing, indicating ongoing investment in growth and development [4]. - The company plans to carry forward the undistributed profits to the next fiscal year, reflecting a focus on reinvestment rather than immediate shareholder returns [7]. - The company reported a significant increase in revenue, with a year-over-year growth of 15% in the diagnostics segment [15]. - The company's operating revenue for 2022 reached ¥5,534,792,784.45, representing a year-on-year increase of 94.95% [27]. - The net profit attributable to shareholders for 2022 was ¥1,827,900,394.20, a growth of 53.19% compared to the previous year [27]. - The net cash flow from operating activities increased by 99.37% year-on-year, amounting to ¥1,964,878,081.19, driven by improved collection of receivables [29]. - The total assets of the company at the end of 2022 were ¥4,890,999,989.86, reflecting a 39.77% increase from the previous year [27]. - The basic earnings per share for 2022 were ¥31.18, up 53.14% from ¥20.36 in 2021 [28]. - The company's net assets attributable to shareholders increased by 48.95% to ¥3,778,150,295.65 by the end of 2022 [29]. Research and Development - The company is investing 15% of its revenue into R&D for new technologies and product innovations [15]. - Research and development expenditure as a percentage of operating revenue was 3.36%, a decrease of 0.40 percentage points from the previous year [28]. - The company has a research team of 254 members, with 41.34% holding master's degrees or higher [39]. - R&D investment increased by 74.26% year-on-year, totaling approximately CNY 185.82 million, driven by increased personnel and material costs [63][64]. - The company has developed over 600 products, widely used in infectious disease prevention, clinical testing, large-scale population screening, and reproductive health management [57]. - The company is focusing on POCT technology, which offers rapid, simple, and cost-effective diagnostic solutions, promoting the development of compact and intelligent diagnostic products [55]. Market Expansion and Strategy - The company is expanding its market presence in Europe, targeting a 25% increase in sales in that region over the next year [15]. - The company is actively expanding its market presence and capabilities in response to the growing demand for molecular diagnostics, particularly in the context of the COVID-19 pandemic [52]. - The company is leveraging its proprietary technology platform to maintain a competitive edge in the molecular diagnostics field, particularly in multiplex fluorescent quantitative PCR technology [53]. - The company is implementing a global marketing strategy to target key market areas based on the development of its overseas business [122]. - The company is exploring potential acquisitions to further enhance its product offerings and market presence [133]. Corporate Governance - The audit report issued by Lixin Certified Public Accountants confirmed the financial statements' accuracy and completeness [6]. - The company has not disclosed any special arrangements in corporate governance that would affect the report's integrity [10]. - The board of directors consists of 8 members, including 3 independent directors, ensuring compliance with governance regulations [126]. - The company has established a complete organizational structure, maintaining independence from the controlling shareholder in business, assets, personnel, and finance [127]. - The company has implemented a robust information disclosure management system, ensuring timely and accurate communication with investors [128]. Operational Risks and Challenges - The company has outlined various operational risks and corresponding mitigation strategies in the management discussion section of the report [4]. - The company faces risks of significant performance decline due to reduced demand for COVID-related products and services as the pandemic situation evolves [74]. - The company is at risk of new product development failures due to long R&D cycles (3-5 years) and high uncertainty in the diagnostics market [76]. - The company has a risk of intensified market competition, which could adversely affect its operational performance and profitability [78]. Social Responsibility and ESG - The company emphasizes ESG integration into its operations, focusing on environmental protection and social responsibility, particularly in response to the COVID-19 pandemic [170]. - The company has donated 4.095 million RMB to various charitable causes, including 1 million RMB to Fudan University for a special care fund [181][183]. - The company has not been classified as a key pollutant discharge unit and has met all environmental compliance standards during the reporting period [174]. - The company has implemented measures to ensure zero solid waste discharge during its operations by classifying and properly disposing of hazardous and non-hazardous waste [177]. Employee Management and Compensation - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to RMB 1,178.80 million [142]. - The company has established a comprehensive compensation policy that includes project bonuses and performance bonuses to motivate employees [155]. - The company emphasizes employee training, implementing annual training plans to enhance overall employee skills and capabilities [156]. - The employee composition includes 254 production staff, 422 sales personnel, 254 technical staff, 21 financial staff, and 131 administrative staff [154].

重要内容提示： 2022 年第三季度报告 证券代码：688399 证券简称：硕世生物 江苏硕世生物科技股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | | | 本报告期比上 | | 年初至报告期末 | | --- | --- | --- | --- | --- | | 项目 | 本报告期 | 年同期增减变 | 年初至报告期末 | 比上年同期增减 | | | | 动幅度(%) | | 变动幅度(%) | | 营业收入 | 1,027,556,396.43 | -1.32 | 4,293,492,259.77 | 97. ...

Financial Performance - The company reported a total revenue of 500 million RMB for the first half of 2022, representing a year-on-year increase of 20%[1]. - The company reported a revenue of RMB 100 million for the first half of 2022, reflecting a year-on-year growth of 15%[11]. - The company's revenue for the first half of 2022 reached approximately CNY 3.27 billion, representing a growth of 188.88% compared to the same period last year[22]. - The company achieved operating revenue of 3,265.94 million yuan, a year-on-year increase of 188.88%[56]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion in Q2 2023, representing a 25% year-over-year growth[114]. - The company provided guidance for Q3 2023, expecting revenue to be between 1.6 billion and 1.7 billion, indicating a growth rate of approximately 20%[114]. - Revenue from COVID-19 nucleic acid testing reagents reached 1,341.67 million yuan, up 210.93% year-on-year[56]. - The net profit attributable to shareholders for the same period was approximately CNY 1.23 billion, an increase of 145.71% year-over-year[22]. - The net profit for the first half of 2022 was ¥1,233,530,249.14, compared to ¥502,032,917.16 in the first half of 2021, reflecting a growth of approximately 145%[161]. User Growth and Market Expansion - User data indicates an increase in active users by 15%, reaching a total of 1.2 million users[1]. - User data indicates an increase in active users by 20% compared to the same period last year, reaching a total of 1 million active users[12]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[11]. - Market expansion plans include entering two new provinces, projected to increase market share by 5%[1]. - Market expansion plans include entering three new international markets by Q4 2023, projected to increase overall market share by 10%[114]. Research and Development - The company is investing 30 million RMB in R&D for new technologies aimed at enhancing product efficiency[1]. - Investment in R&D for new technologies has increased by 25%, focusing on in vitro diagnostic reagents and molecular diagnostics[12]. - The total R&D investment for the reporting period reached approximately ¥105.53 million, a significant increase of 187.72% compared to ¥36.68 million in the same period last year[43]. - The company has developed over 600 types of nucleic acid detection products, covering more than 300 disease control centers across various provinces in China[33]. - The company has a strong pipeline of projects, including clinical mass spectrometry detection series and automation intelligent diagnostic devices, with ongoing investments to enhance diagnostic capabilities[46]. - The company has maintained a strong focus on R&D, with total R&D personnel compensation reaching RMB 25.4 million, up from RMB 14.96 million in the previous year[52]. Strategic Initiatives - The company has provided a forward guidance of 10% revenue growth for the second half of 2022[1]. - New product launches are expected to contribute an additional 50 million RMB in revenue by the end of 2022[1]. - A strategic acquisition of a local biotech firm is expected to enhance the company's product portfolio and accelerate growth in the diagnostics sector[12]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 100 million RMB allocated for this purpose[1]. - The company is exploring partnerships with healthcare providers to enhance point-of-care testing capabilities, aiming for a 50% increase in testing volume by 2023[12]. Financial Health and Risks - The company has identified key risks including regulatory changes and market competition, with mitigation strategies in place[1]. - The net cash flow from operating activities increased by 2,558.90% to approximately CNY 851.74 million, driven by improved collection of receivables[22]. - The company reported a rapid increase in accounts receivable, with a net value of CNY 893.74 million, raising concerns about potential bad debts[66]. - The company faces risks from intensified market competition and potential price declines for diagnostic reagents due to regulatory changes[66][67]. - The company acknowledges the unsustainable nature of its recent growth driven by COVID-19 testing products, with future performance uncertain[69]. Corporate Governance and Compliance - No significant non-operational fund occupation by controlling shareholders was reported[1]. - The company has ensured compliance with related party transaction approval procedures and information disclosure obligations[121]. - There were no significant lawsuits or arbitration matters during the reporting period[121]. - The company has committed to minimizing related party transactions and ensuring fair pricing based on market principles[121]. - The company will ensure compliance with legal obligations and commitments made during the issuance and listing process, accepting supervision from regulatory bodies and investors[97]. Shareholder and Dividend Policies - The company plans to prioritize cash dividends, aiming for a minimum of 10% of distributable profits to be distributed in cash if no major investments are planned[106]. - The company plans to maintain a cash dividend ratio of at least 20% if significant capital expenditures occur, ensuring a minimum of 30% of the average annual distributable profits over the last three years are distributed[106]. - The company will communicate with shareholders, especially minority shareholders, to gather feedback on dividend proposals[109]. - The company reported a net profit distribution of CNY -322,410,000.00 for the current period, indicating a loss allocation to shareholders[195]. Operational Efficiency - The management highlighted a strategic focus on digital transformation to improve operational efficiency[1]. - The company aims to reduce operational costs by 15% through efficiency improvements and process optimization initiatives[114]. - The company is committed to continuous innovation and has formed a multidisciplinary R&D team to drive future growth[53]. Product Development and Innovation - The company has launched products in the POCT field, including antigen test kits for influenza, generating revenue[102]. - The introduction of lyophilized reagent technology is expected to reduce transportation costs and extend shelf life, with some products already available in this format[102]. - The company is enhancing its product offerings by integrating advanced technologies like AI and big data for automated testing solutions[102].

Financial Performance - The company's operating revenue for Q1 2022 reached ¥1,521,902,378.62, representing a year-on-year increase of 77.69%[3] - Net profit attributable to shareholders was ¥631,070,096.78, reflecting a growth of 62.90% compared to the same period last year[3] - Basic earnings per share increased to ¥10.77, up 62.93% year-on-year[3] - Operating profit for Q1 2022 was ¥744,064,455.92, up 62.2% from ¥458,996,646.78 in Q1 2021[16] - Net profit attributable to shareholders for Q1 2022 was ¥631,070,096.78, representing a 63.0% increase from ¥387,386,296.05 in Q1 2021[17] - Basic and diluted earnings per share for Q1 2022 were both ¥10.77, compared to ¥6.61 in Q1 2021[17] Cash Flow - The net cash flow from operating activities surged to ¥490,379,975.90, a significant increase of 1,930.58%[3] - Cash flow from operating activities for Q1 2022 was ¥490,379,975.90, a substantial increase from ¥24,149,786.61 in Q1 2021[20] - The company reported a net cash outflow from investing activities of ¥102,147,782.14 in Q1 2022, compared to a net outflow of ¥113,752,091.23 in Q1 2021[21] - The company experienced a net cash inflow from financing activities of ¥26,317,774.10 in Q1 2022, reversing a net outflow of ¥21,278,982.87 in Q1 2021[21] Assets and Liabilities - Total assets at the end of the reporting period amounted to ¥4,405,110,023.38, marking a 25.88% increase from the previous year[4] - The company's current assets totaled RMB 3,399,578,863.64, up from RMB 2,538,882,061.99, indicating a rise of about 33.9% year-over-year[11] - The total liabilities of the company amounted to RMB 1,237,590,025.15, compared to RMB 962,893,709.40, which is an increase of approximately 28.5%[13] - The company's equity attributable to shareholders reached RMB 3,167,519,998.23, up from RMB 2,536,449,901.45, representing a growth of about 25%[13] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,309[9] - The largest shareholder, Shaoxing RunKang Biological Pharmaceutical Equity Investment Partnership, held 26.61% of the shares, totaling 15,600,000 shares[9] Research and Development - Research and development expenses totaled ¥27,149,529.76, an increase of 65.07% year-on-year, accounting for 1.78% of operating revenue[3] - Research and development expenses for Q1 2022 were ¥27,149,529.76, up from ¥16,447,398.35 in Q1 2021, indicating a focus on innovation[16] Inventory and Receivables - Accounts receivable rose significantly to RMB 685,085,074.84, compared to RMB 342,578,380.56, marking an increase of about 100%[11] - Inventory levels increased to RMB 344,279,186.31 from RMB 250,346,454.01, indicating a rise of approximately 37.5%[12] Other Information - The company reported non-recurring gains of ¥6,311,173.46 for the period[6] - The company has not disclosed any new product or technology developments in this report[11] - There are no significant mergers or acquisitions reported during this period[11] - Total operating costs for Q1 2022 were ¥773,671,474.64, an increase of 93.6% from ¥399,799,615.17 in Q1 2021[16] - The company reported a significant increase in contract liabilities, which rose to RMB 184,179,624.49 from RMB 66,210,879.00, reflecting a growth of about 178%[12]

Financial Performance - The company reported a total revenue of RMB 1.5 billion for the year 2021, representing a year-over-year growth of 20%[11]. - The company's operating revenue for 2021 reached ¥2,839,036,343.41, representing a year-on-year increase of 63.19% compared to ¥1,739,680,701.97 in 2020[23]. - The net profit attributable to shareholders for 2021 was ¥1,193,214,259.45, a 45.59% increase from ¥819,567,339.93 in 2020[23]. - The net profit after deducting non-recurring gains and losses was ¥1,139,627,729.29, reflecting a 45.83% increase from ¥781,455,411.27 in the previous year[23]. - The company's total assets increased by 53.64% to ¥3,499,343,610.85 at the end of 2021, up from ¥2,277,673,271.40 at the end of 2020[23]. - The basic earnings per share for 2021 were ¥20.36, a 45.64% increase compared to ¥13.98 in 2020[24]. - The cash flow from operating activities for 2021 was ¥985,522,925.81, a slight increase of 5.30% from ¥935,881,451.61 in 2020[23]. - The company reported a total revenue of 2,839.04 million RMB in 2021, representing a year-on-year growth of 63.19%[33]. - Revenue from COVID-19 nucleic acid testing reagents reached 1,038.76 million RMB, a 96.06% increase compared to the previous year[34]. - The net profit attributable to shareholders for Q1 was 387.39 million RMB, while Q2 was 114.65 million RMB, Q3 was 494.12 million RMB, and Q4 was 197.06 million RMB[27]. Research and Development - The company invested RMB 200 million in R&D for new technologies, focusing on molecular diagnostics and point-of-care testing solutions[11]. - The company's R&D investment reached 106.64 million yuan, a year-on-year increase of 47.97%, accounting for 3.76% of revenue[36]. - The company has established a cross-disciplinary team of 164 R&D personnel, with 32.93% holding master's degrees or higher[36]. - The company has developed over 600 products utilizing its proprietary core technology platforms, including multiplex fluorescent quantitative PCR, dry chemistry, and automation control[50]. - The company is focusing on high-throughput, closed systems, and timely diagnostics as key technological directions in molecular diagnostics, with NGS and CRISPR technologies being prominent[47]. - The company achieved a prototype completion for home testing instruments, addressing the substantial market demand for home and on-site testing[61]. - The company is accelerating the R&D of upstream core raw materials such as enzymes, antigens, and antibodies to form a complete industry chain from raw materials to instruments and services[111]. Market Expansion and Strategy - The company expects a revenue growth guidance of 25% for the next fiscal year, projecting revenues to reach RMB 1.875 billion[11]. - Market expansion efforts included entering three new international markets, aiming for a 30% increase in international sales[12]. - The company plans to continue its integrated development strategy of "core raw materials + reagents + instruments + services" to promote sustainable growth[35]. - The company is exploring acquisition opportunities in the tech sector, with a budget of $100 million allocated for potential deals[126]. - A new strategic partnership has been established with a leading tech firm to co-develop innovative solutions, expected to launch in Q3 2024[126]. - The company aims to enhance its marketing network by optimizing and integrating distributors and improving direct sales to end customers[114]. Corporate Governance and Compliance - The audit report issued by Lixin Certified Public Accountants is a standard unqualified opinion[4]. - The company has not disclosed any special arrangements for corporate governance[5]. - The company has not faced any situations where more than half of the directors cannot guarantee the authenticity, accuracy, and completeness of the annual report[7]. - The company has established a comprehensive internal governance structure, ensuring effective separation of responsibilities among the shareholders' meeting, board of directors, and supervisory board[161]. - The company has committed to integrating ESG principles into its operations, focusing on environmental protection, social responsibility, and corporate governance[160]. - The company has maintained stable cooperation with suppliers and customers, ensuring mutual benefits and respect for rights[176]. Risk Management - The company has detailed various operational risks and corresponding countermeasures in the report[4]. - The company experienced increased competition in the market, leading to a decrease in profit margins for COVID-19 related products despite revenue growth[25]. - The company faces risks in new product development due to long development cycles of 3-5 years and high R&D failure rates[71]. - There is a risk of core technology leakage, as the company has only patented some key technologies and maintains strict confidentiality measures[71]. - The company anticipates intensified market competition and potential price declines for its reagent products due to regulatory changes and increased market supply[73]. Social Responsibility and Community Engagement - The company actively supported pandemic prevention efforts and contributed to COVID-19 testing initiatives, enhancing its reputation and market presence[34]. - The company donated 2 million RMB and testing reagents to support women's welfare projects and 500,000 RMB to marine education initiatives[172]. - The company has actively participated in social welfare projects, particularly in response to the COVID-19 pandemic, demonstrating its commitment to social responsibility[160]. Employee Relations and Development - The company emphasizes employee training, implementing an annual training plan to enhance overall employee skills and capabilities[150]. - The average salary for R&D personnel decreased to 263,406.10 RMB, down from 328,292.73 RMB in the previous year[67]. - The company has a total of 659,152.25 hours of outsourced labor, with total payments amounting to 15,212,925.50[151]. - The company has established a comprehensive compensation policy that includes project bonuses and performance bonuses to motivate employees[149]. Financial Policies and Shareholder Returns - The company plans to distribute a cash dividend of 100.00 RMB (including tax) for every 10 shares, totaling 586,200,000.00 RMB based on a total share capital of 58,620,000 shares as of December 31, 2021[4]. - The company has a cash dividend policy that stipulates a minimum cash distribution of 10% of the distributable profit if there are no major investment plans or cash expenditures[153]. - The company aims to maintain a stable and continuous profit distribution policy while considering the long-term interests of all shareholders[200]. - The company will prioritize cash dividends when conditions are met, with a preference for cash distribution over stock dividends[200].

2021 年第三季度报告 证券代码：688399 证券简称：硕世生物 江苏硕世生物科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比 上年同期增 | | 年初至报 告期末比 | | --- | --- | --- | --- | --- | | | | 减变动幅度 | 年初至报告期末 | 上年同期 | | | | (%) | | 增减变动 | | | | | | 幅度(%) | | 营业收入 | 1,041,310,736.60 | 97.17 | 2,171 ...